Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Parkinson Disease 4”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06949670
What this trial is testing

Alpha-Synuclein PET/CT in Various α-Syn-Related Disease

Who this might be right for
Alpha Synuclein PathologyAlpha-SynucleinParkinson Disease
Tianjin Medical University 500
Testing effectiveness (Phase 2)Study completedNCT04116073
What this trial is testing

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Who this might be right for
Pancreatic Cancer Non-resectablePancreatic Cancer Metastatic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 25
Testing effectiveness (Phase 2)Ended earlyNCT03361228
What this trial is testing

Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

Who this might be right for
Solid Tumors
Incyte Corporation 5
Not applicableLooking for participantsNCT05740683
What this trial is testing

Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With idiOpathic anosMiA

Who this might be right for
Idiopathic AnosmiaIdiopathic HyposmiaIdiopathic Olfactory Dysfunction
Danish Dementia Research Centre 100
Testing effectiveness (Phase 2)Study completedNCT04924101
What this trial is testing

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

Who this might be right for
Small Cell Lung Cancer
Merck Sharp & Dohme LLC 122
Large-scale testing (Phase 3)Study completedNCT04003636
What this trial is testing

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

Who this might be right for
Biliary Tract Carcinoma
Merck Sharp & Dohme LLC 1,069
Testing effectiveness (Phase 2)Looking for participantsNCT05319730
What this trial is testing

Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Who this might be right for
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 230
Not applicableStudy completedNCT03043768
What this trial is testing

Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease

Who this might be right for
Parkinson's Disease
GWT-TUD GmbH 50
Large-scale testing (Phase 3)Study completedNCT02555657
What this trial is testing

Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

Who this might be right for
Metastatic Triple Negative Breast Cancer
Merck Sharp & Dohme LLC 622
Testing effectiveness (Phase 2)Study completedNCT06036836
What this trial is testing

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Who this might be right for
Solid TumorCutaneous Squamous Cell CarcinomaEndometrial Cancer
Merck Sharp & Dohme LLC 163
Testing effectiveness (Phase 2)Study completedNCT03037203
What this trial is testing

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

Who this might be right for
Excessive SleepinessParkinson Disease
Jazz Pharmaceuticals 66
Early research (Phase 1)Ended earlyNCT03515824
What this trial is testing

Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)

Who this might be right for
NeoplasmsColorectal NeoplasmsHead and Neck Neoplasms
Merck Sharp & Dohme LLC 22
Testing effectiveness (Phase 2)Study completedNCT05007106
What this trial is testing

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Who this might be right for
Uterine Cervical NeoplasmsEndometrial NeoplasmsSquamous Cell Carcinoma of Head and Neck+8 more
Merck Sharp & Dohme LLC 613
Testing effectiveness (Phase 2)Study completedNCT04303169
What this trial is testing

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 146
Testing effectiveness (Phase 2)Study completedNCT02735239
What this trial is testing

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Who this might be right for
Esophageal Cancer
Ludwig Institute for Cancer Research 73
Early research (Phase 1)Active Not RecruitingNCT05853367
What this trial is testing

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Who this might be right for
Metastatic Solid TumorsAdvanced Solid Tumors
Merck Sharp & Dohme LLC 95
Large-scale testing (Phase 3)Ended earlyNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 480
Testing effectiveness (Phase 2)Active Not RecruitingNCT06504394
What this trial is testing

Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

Who this might be right for
Classical Hodgkin Lymphoma RecurrentClassical Hodgkin Lymphoma RefractoryPrimary Mediastinal Large B-cell Lymphoma Recurrent+1 more
Merck Sharp & Dohme LLC
Large-scale testing (Phase 3)Looking for participantsNCT06345729
What this trial is testing

Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 600
Not applicableStudy completedNCT00105131
What this trial is testing

Genetic Characterization of Parkinson's Disease

Who this might be right for
Parkinson DiseasePDMovement Disorder+2 more
National Institute of Neurological Disorders and Stroke (NINDS) 2,500
Next Page
66